Solid Biosciences Inc. Payments for (Proceeds from) Other Investing Activities
Solid Biosciences Inc. (SLDB) reported Payments for (Proceeds from) Other Investing Activities of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-08-06
- Solid Biosciences Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was $0.00.
- Solid Biosciences Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-06-30 was -$85.00K.
- Solid Biosciences Inc. payments for (proceeds from) other investing activities for the quarter ending 2025-03-31 was $0.00.
- Solid Biosciences Inc. payments for (proceeds from) other investing activities for the quarter ending 2024-09-30 was $0.00.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$85.00K derived: sum of 2 quarters · filed 2026-08-06 | -$85.00K 10-Q · filed 2025-11-03 |
| 2025-06-30 | -$85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$85.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | -$5.00K 10-Q · filed 2025-11-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$5.00K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | -$5.00K 10-Q · filed 2025-05-15 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |